Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Susan Galbraith
Pharma
As AZ hits $45B revenue goal, is Enhertu nearing a plateau?
Enhertu's new patient share in HER2-low breast cancer appears to have flattened, raising questions about the indication's real market opportunity.
Angus Liu
Feb 8, 2024 10:48am
AZ's Imfinzi falls short in lung cancer trial
Dec 19, 2022 9:30am
AstraZeneca's blockbuster Imfinzi flunks cervical cancer trial
Mar 24, 2022 9:26am
AZ's R&D chiefs talk roxadustat, Imfinzi-treme
Feb 10, 2022 10:13am
AZ oncology R&D chief marks Imfinzi as 'core backbone'
Jan 20, 2022 2:40pm
